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Aptamers, sometimes termed ‘‘chemical antibodies,’’ have been engineered into multimerized versions for
therapeutic application. The groups of Gilboa and Sullenger now report the development of a bivalent ap-
tamer-molecular device as a receptor agonist that has the same functional properties, but stronger avidity
than a corresponding antibody.Aptamers are in vitro selected nucleic
acids that assume specific and stable
three-dimensional shapes, thereby pro-
viding highly specific, tight binding to tar-
geted ligands. Many aptamer properties
are comparable to those of protein mono-
clonal antibodies, but the nucleic acid
nature of aptamers offers more exciting
advantages (Nimjee et al., 2005), includ-
ing the potential for chemical synthesis,
convenient modification, chemical versa-
tility, stability, and lack of immunogenic-
ity. Therefore, aptamers can be utilized
for a variety of applications ranging from
diagnostics to therapeutics (Pestourie
et al., 2005; Famulok et al., 2007). Re-
cently, bivalent or multivalent aptamer-
based molecules have been engineered
via different methods to serve as diagnos-
tic probes (Fredriksson et al., 2002), deliv-
ery vectors (Chu et al., 2006), antiviral
agents (Darfeuille et al., 2001), and recep-
tor agonists (McNamara et al., 2008).
Aptamers targeting cell surface recep-
tors have been demonstrated tomodulate
immune responses in vivo, hence attract-
ing renewed attention in the field of ap-
tamer development. In particular, multi-
merized versions of aptamers have been644 Chemistry & Biology 15, July 21, 2008successfully engineered and these have
enhanced efficacy over monovalent ap-
tamers. This has been attributed to local
cooperative interactions of multimeric
aptamers and their cognate receptors.
One such approach for aptamer multime-
rization has been described by Santulli-
Marotto et al. (2003). These investigators
used four cytotoxic T cell antigen (CTLA)
aptamers annealed to a complementary
DNA scaffold which resulted in enhanced
binding affinity without changing the
functionality of the individual aptamer
units. Similarly, McNamara et al. (2008)
described that multivalent configurations
of the 4-1BB aptamers costimulated
T cell activation in vitro and promoted tu-
mor rejection in vivo (Figure 1A), thus ex-
ploiting the biological role of 4-1BB as
a T cell costimulatory receptor that pro-
longs cell survival. In this study aptamer
dimers were generated by adding short
complementary sequences to the 30-
ends of the aptamers and allowing them
to anneal in pair-wise fashion. However,
the 21 nucleotide linker in this molecular
device limited the molecular distance
and structural flexibility as well as in vitro
transcribed RNA yields.ª2008 Elsevier Ltd All rights reservedIn this issue, Sullenger and colleagues
(Dollins et al., 2008) describe multivalent
configurations of the OX40 aptamer
(Figure 1B) which costimulated T cell
activation in vitro and promoted tumor
rejection in vivo. In this study, 20-fluoro
pyrimidine RNA aptamers with nanomolar
binding constants for the OX40 receptor
were isolated using a standard bead-
based SELEX method. Initially, although
capable of binding OX40, the selected
monomeric aptamers were unable to
stimulate OX40 function. This was not
surprising since the crystal structure of
the OX40-OX40 ligand complex revealed
multiple binding sites for its ligand,
whereas an average of one aptamer was
bound to a single receptor.
Considering the features of multiple
ligand binding sites on OX40, these re-
searchers developed a malleable, DNA
oligonucleotide-based molecular scaffold
which was able to bind two copies of the
aptamer. A polyethylene spacer (18 car-
bons in length) was inserted between the
aptamer annealing sites on the scaffold
to provide flexibility (Figure 1B). With this
scaffold, two OX40 aptamers were ar-
ranged in a flexible conformation, spaced
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receptor and trigger multimerization,
thereby activating receptor function. This
attractive scaffold-based approach can
also be employed to accommodate
various intermolecular distances and
conformations. In this strategy, the 20 nt
DNA scaffold is annealed with the 30-end
of the aptamer. As part of the aptamer,
this sequence of 20 nt when annealed
with the scaffold should not affect the
active structure and hence binding affinity
of the aptamer. Generally, if the selected
aptamers cannot be truncated without
affecting the original binding affinity, an
additional tail can be attached to the
aptamer for annealing with a molecular
scaffold.
Fortunately, after the selected OX40
aptamers were annealed with the scaf-
fold, they were still capable of binding
the OX40 receptor, which activated the
OX40 receptor onprimedTcells in culture.
By contrast, a monomer aptamer or mu-
tant aptamer had no stimulatory effects.
Furthermore, the dimerized aptamer bind-
ing to OX40 significantly enhanced the
antitumorpotencyof dendritic cells in vivo.
Although the work described by Dollins
et al. (2008) focuses on development
of OX40 agonists, structurally flexible,
size-tailored aptamer-molecular devices
could provide a useful means of regulat-
ing many biological processes where
dimerization ormultimerization is required.
As simple and active building blocks, the
various aptamers can also be assembled
with other therapeutic nucleic acids (like
antisense oligonucleotides, ribozymes
and siRNAs) into versatile molecular
devices with multiple functions. With the
publication of this creative aptamer di-
merization method, expect to see many
more applications of aptamers as ago-
nists for receptor activation or antagonists
for blocking receptor function.
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Figure 1. Engineering Aptamer-Based Molecular Devices
(A) The formation of 4-1BB aptamer dimer. The 30-terminus of the 4-1BB aptamers was attached to addi-
tional complementary sequences (20 nt in length; red and green lines shown), which were subsequently
annealed together.
(B) The formation of OX40 aptamer dimer. The 30-end sequences (20 nt) of OX40 aptamers were annealed
to a flexible DNA scaffold. A tandem repeat of 20 nt DNA oligos (red lines) was connected by a flexible poly-
ethylene spacer (green).Chemistry & Biology 15, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 645
